A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma

Cancer

Volumn 95, Issue 8, 2002, Pages 1714-1719

  Popa, Irina E ^a   Stewart, Kathleen ^a   Smith, Frederick P ^a   Rizvi, Naiyer A ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Docetaxel; Gemcitabine; Nonsmall cell lung carcinoma; Phase II trial; Survival; Toxicity

Indexed keywords

DEXAMETHASONE; DOCETAXEL; GEMCITABINE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ANEMIA; ANOREXIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; SURVIVAL ANALYSIS; TAXOIDS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0037108180     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10843     Document Type: Article

References (23)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15-36.
2. Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest. 1994;106:861-865.
3. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer: report of a Canadian multicenter randomized trial. J Clin Oncol. 1988;6:633-641.
4. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2000;18:122-130.
5. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus navelbine in the treatment of advanced non-small cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1998;16:2459-2465.
6. Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000;18:623-631.
7. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98.
8. Bhargava P, Marshall JL, Fried K, et al. Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients administered weekly to patients with advanced cancer. Cancer Chemother Pharmacol. 2001;48:95-103.
9. Andersson BS, Luna MA, Yee C, et al. Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia. Cancer. 1990;65:1079-1084.
10. Pavlakis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer. 1997;80:286-291.
11. Semb KA, Aamdal S, Oian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol. 1998;15:3426-3432.
12. Etienne B, Perol M, Nesme P, et al. Acute diffuse interstitial pneumopathy following docetaxel (Taxotere). Apropos of 2 cases. Rev Mal Respir. 1998;15:199-203.
13. Read WL, Mortimer JE, Picus J. Severe interstitial pneumonitis associated with docetaxel administration. Cancer. 2002; 94:847-853.
14. Rebattu P, Quantin X, Ardiet C, et al. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer. Lung Cancer. 2001;33:277-287.
15. Dunsford ML, Mead GM, Bateman AC, et al. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol. 1999;10:943-947.
16. Thomas AL, Cox G, Sharma RA, et al. Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study. Eur J Cancer. 2000;36:2329-2334.
17. Georgoulias V, Kouroussis C, Androulakis N, et al. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial. J Clin Oncol. 1999;17:914-920.
18. Ventriglia M, Estevez R, Alume H, et al. Docetaxel (Taxotere) plus gemcitabine (Gemtro). A new combination in the treatment of patients with advanced non-small cell lung cancer. A preliminary analysis [abstract 365]. Ann Oncol. 1998;9:96.
19. Rubio G, Blajman C, Capó, A, et al. Docetaxel and gemcitabine in metastatic non-small-cell lung cancer (NSCLC). A phase II study. Preliminary feasibility report. Proc Am Soc Clin Oncol. 1999;19:2012a.
20. Hejna M, Kornek GV, Raderer M, et al. Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor. Cancer. 2000;89:516-522.
21. Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet. 2001;357:1478-1484.
22. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 1991;9:1618-1626.
23. Jiroutek M, Johnson D, Blum R, et al. Prognostic factors in advanced non-small cell lung cancer (NSCLC): analysis of Eastern Cooperative Oncology Group trials from 1981-1992 [abstract]. Proc Am Soc Clin Oncol. 1998;17:461.